



LJMU Research Online

Adekunle, Y, Samuel, BB, Ezeude, CM, Nahar, L, Fatokun, AA and Sarker, S

Isolation, cytotoxicity evaluation, and molecular docking of 3,4,3'-tri-O-methylflavellagic acid from *Anogeissus leiocarpus* (DC.) Guill. & Perr. root

<http://researchonline.ljmu.ac.uk/id/eprint/25188/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)


Adekunle, Y, Samuel, BB, Ezeude, CM, Nahar, L, Fatokun, AA and Sarker, S (2025) Isolation, cytotoxicity evaluation, and molecular docking of 3,4,3'-tri-O-methylflavellagic acid from *Anogeissus leiocarpus* (DC.) Guill. & Perr. root. *Natural Product Research*. ISSN 1478-6419

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>



Isolation, cytotoxicity evaluation, and molecular docking of 3,4,3'-tri-*O*-methylflavellagic acid from *Anogeissus leiocarpus* (DC.) Guill. & Perr. root

Yemi A. Adekunle, Babatunde B. Samuel, Chinemenma M. Ezeude, Lutfun Nahar, Amos A. Fatokun & Satyajit D. Sarker

To cite this article: Yemi A. Adekunle, Babatunde B. Samuel, Chinemenma M. Ezeude, Lutfun Nahar, Amos A. Fatokun & Satyajit D. Sarker (11 Jan 2025): Isolation, cytotoxicity evaluation, and molecular docking of 3,4,3'-tri-*O*-methylflavellagic acid from *Anogeissus leiocarpus* (DC.) Guill. & Perr. root, Natural Product Research, DOI: [10.1080/14786419.2025.2451218](https://doi.org/10.1080/14786419.2025.2451218)

To link to this article: <https://doi.org/10.1080/14786419.2025.2451218>



© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



[View supplementary material](#)



Published online: 11 Jan 2025.



[Submit your article to this journal](#)



Article views: 262








[View related articles](#)



[View Crossmark data](#)

Isolation, cytotoxicity evaluation, and molecular docking of 3,4,3'-tri-*O*-methylflavellagic acid from *Anogeissus leiocarpus* (DC.) Guill. & Perr. root

Yemi A. Adekunle^{a,b,c,d} , Babatunde B. Samuel^a , Chinemenma M. Ezeude^d,
Lutfun Nahar^e , Amos A. Fatokun^b  and Satyajit D. Sarker^b 

^aDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ibadan, Ibadan, Oyo State, Nigeria; ^bCentre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John Moores University, Liverpool, UK; ^cDepartment of Pharmaceutical and Medicinal Chemistry, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria; ^dDepartment of Pharmaceutical Chemistry, Dora Akunyili College of Pharmacy, Igbinedion University, Benin City, Edo State, Nigeria; ^eLaboratory of Growth Regulators, Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences, Olomouc, Czech Republic

ABSTRACT


Cancer kills about 10 million people every year. Medicinal plants remain a major source in the global search for anticancer drugs. In this study, 3,4,3'-tri-*O*-methylflavellagic acid (MFA) was isolated from the methanol root extract of *Anogeissus leiocarpus*. The structure was determined by 1D- and 2D-NMR data. The cytotoxic effects of MFA were evaluated against human breast (MCF-7), colorectal (Caco-2), and cervical (HeLa) cancer cell lines using the 3-[4,5-dimethylthiazole-2-yl] 3,5-diphenyltetrazolium bromide assay. A multi-protein target screening *via* molecular docking was conducted against ten cancer-related proteins, and ADMET properties were evaluated. MFA exhibited the most potent activity against Caco-2 (IC₅₀: 46.75 ± 13.00 μM). Molecular docking analysis showed that MFA had a strong binding affinity for the colchicine-binding site of αβ-tubulin and polo-like kinase-1 (binding energies: -8.5 and -8.4 kcal/mol, respectively). MFA also satisfied the Lipinski's Rule of Five. MFA could, therefore, potentially serve as a scaffold for developing new anticancer molecules.

ARTICLE HISTORY


Received 24 May 2024
Accepted 6 January 2025

KEYWORDS

Anogeissus leiocarpus;
3,4,3'-tri-*O*-methylflavellagic acid;
molecular docking;
cancer



CONTACT Yemi A. Adekunle  y.a.adekunle@2022.ljmu.ac.uk, adekunleya@abuad.edu.ng; Babatunde B. Samuel  bb.samuel@mail.ui.edu.ng; Lutfun Nahar  nahar@ueb.cas.cz

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/14786419.2025.2451218>.

© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

1. Introduction

Cancer is a leading cause of morbidity and death globally (Ferlay et al. 2021). It is characterised by abnormal growth of cells and tissues that ultimately leads to invasions and metastases (Meirson et al. 2020). In 2020, more than 19 million new cancer cases and almost 10 million cancer deaths were recorded (Sung et al. 2021). The burdens of cancer have increased in Africa due to the surge in population as well as the high prevalence of risk factors implicated in cancer, such as smoking, obesity, and physical inactivity (Wild et al. 2020).

Chemotherapeutic agents often have adverse effects, displaying activity against rapidly growing cells of the bone marrow, gastrointestinal tract, and hair follicles (Gyanani et al. 2021). This has constantly motivated the search for newer drugs. Nature, through medicinal plants, marine organisms and microbes, has produced molecules which are effective in combating human diseases, including cancer (Newman and Cragg 2020; Sarker et al. 2020). Research attention is being drawn to natural products (NPs) for newer anticancer agents. In the past, medicinal plants, including *Catharanthus roseus* (L.) G. Don, *Camptotheca acuminata* Decne, *Podophyllum peltatum* L., and *Taxus brevifolia* Nutt., produced leading drugs for cancer therapy (Sarker et al. 2020).

Anogeissus leiocarpus (DC.) Guill. & Perr., also known as African birch, is a large deciduous tree native to tropical Africa (Arbab 2014). Its height ranges from 15 to 18 metres, with a diameter of 1 metre (Singh et al. 2016). It is the only West African species of the genus *Anogeissus* and it is commonly distributed in tropical Central and East Africa (Arbab 2014). The stem bark, root, and leaf have traditional uses in the treatment of breast, head and neck, and skin cancers (Malami et al. 2020), diabetes mellitus (Adinortey et al. 2019), malaria (Sanogo et al. 2023), trypanosomiasis (Zongo et al. 2017), tuberculosis (Ofukwu et al. 2008), viral infections (Abubakar et al. 2022), as well as in maintaining mouth and teeth hygiene (Taiwo et al. 1999). The plant contains phytochemicals, including ellagitannins and ellagic acid derivatives (Shuaibu et al. 2008; Akande et al. 2022; Micheli et al. 2023), flavonoids (Attioua et al. 2011) and triterpenes (Chaabi et al. 2008; Akande et al. 2022). The bark predominantly contains ellagitannins and ellagic acid derivatives such as castalagin, di-methyl ellagic acid, di-methyl ellagic acid glucopyranoside and xylopyranoside, di-*O*-methylflavellagic acid, flavogallonic acid, punicalagin, tri-methyl ellagic acid, tri-*O*-methylflavellagic acid (Salih et al. 2017; Orlando et al. 2019; Akande et al. 2022). Most of these compounds have not been linked to biological activities (Adekunle et al. 2024).

Molecular docking has become an increasingly important drug discovery tool (Meng et al. 2011; Sarker and Nahar 2018). It is a simulation approach that models the interactions of small molecules (ligands) on the active sites of proteins (receptors) (Ainsley et al. 2018). It can predict the binding orientation of a ligand on the active site of a protein. It can also assess the binding affinity (Meng et al. 2011). To describe a drug's pharmacokinetic properties, its toxicity and drug-likeness are evaluated (Han et al. 2019). Consequently, drug-likeness and bioavailability predictions (Lipinski 2000) were evaluated for the ellagic acid derivative isolated and identified in the present study. The compound was tested on three cancer cell lines and was docked against ten selected cancer-related protein targets.

2. Results and discussion

Compound Q1, 2.5 mg, was obtained as a yellow flake which precipitated out of column-chromatographed *n*-hexane/ethyl acetate fractions (Figure 1). FTIR spectrum showed peaks at 3450 cm^{-1} (OH stretching), 3000 cm^{-1} and 2910 cm^{-1} (CH stretching), 1720 cm^{-1} and 1680 cm^{-1} (C = O stretching), 1610 cm^{-1} (C = C stretching), and 1010 cm^{-1} (C-O stretching) (Figure S10). ^1H NMR spectrum (DMSO- d_6) exhibited one aromatic proton signal at δ_{H} 7.53 s (H-5'); and three methoxy protons at δ_{H} 3.89 s (CH_3 -3), 4.04 s (CH_3 -4) and 4.14 s (CH_3 -3') (Figure S7). Seventeen (17) carbon signals were observed in the ^{13}C -DEPT-Q spectrum (Figures S8 and S9), including one aromatic peak at δ_{C} 112.2 (C-5'); three methoxy groups at δ_{C} 61.5 (C-3), 61.7 (C-4), 62.2 (C-3'); and two carbonyl groups (lactone) at δ_{C} 161.4 (C-7) and 158.8 (C-7') (Table S1). Other aromatic peaks were observed between δ_{C} 98.0 and 153.6. Comparing the NMR data with the literature values helped identification of the compound as 3,4,3'-tri-*O*-methylflavellagic acid (MFA) (Adigun et al. 2000; Serafin et al. 2007). MFA (Figure 1) is a flavellagic acid derivative that was first isolated from *Terminalia paniculata* Roth (Combretaceae) (Row and Raju 1967). Its occurrence and that of its 4'-*O*-glucoside has been reported in the stem bark extract of *A. leiocarpus* (Nduji and Okwute 1988; Adigun et al. 2000; Chaabi et al. 2008). Its glucoside inhibited the growth of *Candida albicans*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (Adigun et al. 2000). It has also been reported in *Ruprechtia tangarana* Standl., (Polygonaceae) (Pettit et al. 2003) and *Plinia glomerata* (Myrtaceae) (Serafin et al. 2007).

The methanol extract of the root of *A. leiocarpus* and its dichloromethane fraction had previously been shown to possess activity against human breast adenocarcinoma and rhabdomyosarcoma cell lines (Adekunle et al. 2022). In this follow-up study, a compound (MFA) was isolated from the dichloromethane fraction and its cytotoxic effects were evaluated against human colorectal cancer cell line (Caco-2), human cervical cancer cell line (HeLa), and human breast cancer cell line (MCF-7) using the *in vitro* MTT assay. MFA showed most potent cytotoxic effect against Caco-2 as shown in Table S2. The second most sensitive cell line was MCF-7. Vincristine was used as the reference anticancer drug. MFA could be one of the secondary metabolites responsible for the anticancer activity




Figure 1. Structure of 3,4,3'-tri-*O*-methylflavellagic acid isolated from *A. leiocarpus* root.

of the root of *A. leiocarpus* (Salau et al. 2013; Hassana et al. 2018; Alqathama et al. 2020). MFA has been shown to have other biological activities. For example, a previous study noted the profound antinociceptive effects of MFA and its 4'-O-glucoside, with calculated ID_{50} value of 10.8 and 2.5 $\mu\text{mol/kg}$, respectively, when injected intraperitoneally, against writhing in mice. Comparison with the standard drugs aspirin, diclofenac, dipyrrone, and paracetamol with ID_{50} values of 133.1, 38.0, 162, and 125.8 $\mu\text{mol/kg}$, respectively, showed MFA and its 4'-O-glucoside were more potent (Serafin et al. 2007).

Molecular docking was carried out to gain insights into the mechanisms of inhibitory potential of MFA against cancer-related targets (Oluyemi et al. 2022). MFA was observed to dock well with the selected proteins (Table S3). The compound showed highest binding affinity for $\alpha\beta$ -tubulin (1SA0) at the colchicine-binding site, having a binding energy of -8.5 kcal/mol. The next two highest binding energies (-8.4 and -8.3 kcal/mol, respectively) were observed for polo-like kinase-1, PLK-1 (3FC2) and epidermal growth factor receptor tyrosine kinase, EGFR (1M17).

The $\alpha\beta$ -Tubulin heterodimer is a subunit of the microtubule, a cyto-motive protein filament found in the cytoskeleton of nearly all eukaryotic cells (Tuszyński et al. 2005). Microtubules assemblage dynamics can be disturbed by various compounds, including vinca alkaloids (vincristine, vinblastine), colchicine, podophyllotoxin, and macrolides (Amos 2011). Critical residues that are involved in hydrophilic and hydrophobic interactions at the colchicine binding site include THR179, ALA180, ASN101, LEU248, ALA316, LYS352 (Wang et al. 2022). Analysis of the molecular docking result of MFA with $\alpha\beta$ -tubulin showed multiple hydrogen bonding with SER178, ASN258, ALA317, and LYS352; π -alkyl interactions with CYS241, LEU248, LEU255, ALA316, and ALA354; and van der Waals interactions with THR179, ALA180, ASN101, LYS254, VAL318, and THR353 (Figure S2). These residues including CYS241 have been shown to be involved in the binding of colchicine to the receptor (Naaz et al. 2019).

MFA interacted with PK-1 *via* hydrogen bonding with CYS67, LYS82, GLU131, and ASP194. Carbon hydrogen bonding was observed with CYS133 and LEU59. MFA also showed π - π stacked interactions with PHE183. It formed π -alkyl interactions with two residues, ALA80 and LEU130 (Figure S3). The interactions of MFA with EGFR kinase include hydrogen bonding with MET769; carbon hydrogen bonding with GLU738 and ASP831; π -sigma bond with VAL702; and π -alkyl interactions with LEU694, ALA719, LYS721, and LEU820 (Figure S4).

Some physicochemical properties have been used in predicting the absorption and other pharmacokinetic parameters of small molecule drugs. These include the molecular weight, hydrogen bond acceptor, hydrogen bond donor, $\log P$ and topological polar surface area (Lipinski 2000). MFA did not violate Lipinski's Rule of Five as shown in Table S4. The bioactivity radar (Figure S5) shows that MFA bioavailability rating was slightly within the suitable physicochemical space for oral bioavailability (www.swissadme.ch).

Docking poses were visualised by BIOVIA Discovery Studio Visualiser (Baroroh et al. 2023).

4. Conclusions

Natural products have played a pivotal role in cancer drug discovery. A bioactive compound-3,4,3'-tri-O-methylflavellagic acid (MFA), which was isolated from the

methanol root extract of *Anogeissus leiocarpus*, had shown inhibitory activity against three human cancer cell lines. Molecular docking against ten cancer-related targets revealed that it had good binding affinity for the colchicine binding site of tubulin. Drug-likeness study also revealed that the compound conformed with Lipinski's drug pharmacokinetics parameters. Based on these findings, MFA could be considered a potential template for developing new anticancer agents.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This project was supported by the Commonwealth Scholarship Commission, United Kingdom [NGCN-2021-184], European Regional Development Fund – Project ENOCH [No. CZ.02.1.01/0.0/0.0/16_019/0000868], and the Czech Agency Grants – Project 23-05474S and Project 23-05389S.

ORCID

Yemi A. Adekunle  <http://orcid.org/0000-0002-9392-3925>
Babatunde B. Samuel  <http://orcid.org/0000-0001-5553-4438>
Lutfun Nahar  <http://orcid.org/0000-0002-1157-2405>
Amos A. Fatokun  <http://orcid.org/0000-0001-5183-7589>
Satyajit D. Sarker  <http://orcid.org/0000-0003-4038-0514>

References

- Abubakar IB, Kankara SS, Malami I, Danjuma JB, Muhammad YZ, Yahaya H, Singh D, Usman UJ, Ukwuani-Kwaja AN, Muhammad A, et al. 2022. Traditional medicinal plants used for treating emerging and re-emerging viral diseases in northern Nigeria. *Eur J Integr Med.* 49:102094. doi:10.1016/j.eujim.2021.102094.
- Adekunle YA, Samuel BB, Akinleye TE, Adeniji AJ, Ogbale OO. 2022. Cytotoxicity analysis of nineteen medicinal plants extracts on breast adeno-carcinoma (MCF-7) and rhabdomyosarcoma (RD) cancer cell lines. *Trends Pharm Sci.* 8(1):57–64. doi:10.30476/TIPS.2022.94313.1136.
- Adekunle YA, Samuel BB, Nahar L, Fatokun AA, Sarker SD. 2023. Cytotoxic triterpenoid saponins from the root of *Olox subscorpioidea* Oliv. (Olacaceae). *Phytochemistry.* 215:113853. doi:10.1016/j.phytochem.2023.113853.
- Adekunle YA, Samuel BB, Nahar L, Fatokun AA, Sarker SD. 2024. *Anogeissus leiocarpus* (DC.) Guill. & Perr. (Combretaceae): a review of the traditional uses, phytochemistry and pharmacology of African birch. *Fitoterapia.* 176:105979. doi:10.1016/j.fitote.2024.105979.
- Adeyemi AT, Mosebi S. 2023. Characteristic binding landscape of estrogen receptor- α 36 protein enhances promising cancer drug design. *Biomolecules.* 13(12):1798. doi:10.3390/biom13121798.
- Adeyemi AT, Oluyemi WM, Adekunle YA, Adeyemi N, Alahmdi MI, Soliman MES, Abo-Dya NE. 2023. Propitious indazole compounds as β -ketoacyl-ACP synthase inhibitors and mechanisms unfolded for TB cure: integrated rational design and MD simulations. *ChemistrySelect.* 8(3):e202203877. doi:10.1002/slct.202203877.
- Adigun JO, Amupitan JO, Kelly DR. 2000. Isolation and investigation of antimicrobial effect of 3,4,3'-tri-O-methylflavellagic acid and its glucoside from *Anogeissus leiocarpus*. *B Chem Soc Ethiopia.* 14(2):169–174. doi:10.4314/bcse.v14i2.20982.

- Adinortey MB, Agbeko R, Boison D, Ekloh W, Kuatsienu LE, Biney EE, Affum OO, Kwarteng J, Nyarko AK, Carvalho JCT. 2019. Phytomedicines used for diabetes mellitus in Ghana: a systematic search and review of preclinical and clinical evidence. *Evid Based Complement Alternat Med.* 2019:6021209. doi:10.1155/2019/6021209.
- Ainsley J, Lodola A, Mulholland AJ, Christov CZ, Karabencheva-Christova TG. 2018. Combined quantum mechanics and molecular mechanics studies of enzymatic reaction mechanisms. *Adv Protein Chem Struct Biol.* 113:1–32. doi:10.1016/bs.apcsb.2018.07.001.
- Akande T, Khatib M, Salawu SO, Akindahunsi AA, Di Cesare Mannelli L, Ghelardini C, Balli D, Cecchi L, Mulinacci N. 2022. ¹H NMR and HPLC-DAD-MS for the characterization of ellagitannins and triterpenoids of less investigated *Anogeissus leiocarpus* DC (Combretaceae) stem bark. *Food Chem.* 375:131813. doi:10.1016/j.foodchem.2021.131813.
- Alqathama A, Ezuruike UF, Mazzari ALDA, Yonbawi A, Chieli E, Prieto JM. 2020. Effects of selected Nigerian medicinal plants on the viability, mobility, and multidrug-resistant mechanisms in liver, colon, and skin cancer cell lines. *Front Pharmacol.* 11:546439. doi:10.3389/fphar.2020.546439.
- Amos LA. 2011. What tubulin drugs tell us about microtubule structure and dynamics. *Semin Cell Dev Biol.* 22(9):916–926. doi:10.1016/j.semcdb.2011.09.014.
- Arbab AH. 2014. Review on *Anogeissus leiocarpus* a potent African traditional drug. *Int J Res Pharm Chem.* 4(3):496–500.
- Attioua B, Lagnika L, Yeo D, CA, Kaiser M, Weniger B, Lobstein A, Vonthron-Sénécheau C. 2011. *In vitro* antiplasmodial and antileishmanial activities of flavonoids from *Anogeissus leiocarpus* (Combretaceae). *Int J Pharm Sci Rev Res.* 11(2):1–7.
- Baroroh U, Muscifa ZS, Destiarani W, Rohmatullah FG, Yusuf M. 2023. Molecular interaction analysis and visualization of protein-ligand docking using Biovia Discovery Studio Visualizer. *Indones J Comput Biol.* 2(1):22–30. doi:10.24198/ijcb.v2i1.46322.
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. 2000. The Protein Data Bank. *Nucleic Acids Res.* 28(1):235–242. doi:10.1093/nar/28.1.235.
- Chaabi M, Benayache S, Benayache F, N’Gom S, Koné M, Anton R, Weniger B, Lobstein A. 2008. Triterpenes and polyphenols from *Anogeissus leiocarpus* (Combretaceae). *Biochem Syst Ecol.* 36(1):59–62. doi:10.1016/j.bse.2007.05.007.
- Dallakyan S, Olson AJ. 2015. Small-molecule library screening by docking with PyRx. In: Hempel JE, Williams CH, Hong CC, editors. *Methods in molecular biology.* New York: Springer Science + Business Media, vol. 1263; p. 243–250. doi:10.1007/978-1-4939-2269-7_19.
- Dawicki-McKenna JM, Langelier M, DeNizio JE, Riccio AA, Cao CD, Karch KR, McCauley M, Steffen JD, Black BE, Pascal JM. 2015. PARP-1 activation requires local unfolding of an autoinhibitory domain. *Mol Cell.* 60(5):755–768. doi:10.1016/j.molcel.2015.10.013.
- Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. 2021. Cancer statistics for the year 2020: an overview. *Intl Journal of Cancer.* 149(4):778–789. doi:10.1002/ijc.33588.
- Gyanani V, Haley JC, Goswami R. 2021. Challenges of current anticancer treatment approaches with focus on liposomal drug delivery systems. *Pharmaceuticals.* 14(9):835. doi:10.3390/ph14090835.
- Han Y, Zhang J, Hu CQ, Zhang X, Ma B, Zhang P. 2019. *In silico* ADME and toxicity prediction of ceftazidime and its impurities. *Front Pharmacol.* 10(434):434. doi:10.3389/fphar.2019.00434.
- Hassana LEA, Al-Suade FSR, Fadul SM, Abdul Majid AMS. 2018. Evaluation of antioxidant, anti-angiogenic and antitumor properties of *Anogeissus leiocarpus* against colon cancer. *Angiotherapy.* 1(2):56–66. doi:10.25163/angiotherapy.1200021526100818.
- Lee D, Long SA, Adams JL, Chan G, Vaidya KS, Francis TA, Kikly K, Winkler JD, Sung C, Debouck C, et al. 2000. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. *J Biol Chem.* 275(21):16007–16014. doi:10.1074/jbc.275.21.16007.
- Li Y, Zhao J, Gutgesell L, Shen Z, Ratia K, Dye K, Dubrovskiy O, Zhao H, Huang F, Tonetti DA, et al. 2020. Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib. *J Med Chem.* 63(13):7186–7210. doi:10.1021/acs.jmedchem.0c00456.

- Lipinski CA. 2000. Drug-like properties and the causes of poor solubility and poor permeability. *J Pharmacol Toxicol Methods*. 44(1):235–249. doi:10.1016/s1056-8719(00)00107-6.
- Löwe J, Li H, Downing KH, Nogales E. 2001. Refined structure of $\alpha\beta$ -tubulin at 3.5 Å resolution. *J Mol Biol*. 313(5):1045–1057. doi:10.1006/jmbi.2001.5077.
- Malami I, Jagaba NM, Abubakar IB, Muhammad A, Alhassan AM, Waziri PM, Yahaya IZY, Mshelia HE, Mathias SN. 2020. Integration of medicinal plants into the traditional system of medicine for the treatment of cancer in Sokoto State, Nigeria. *Heliyon*. 6(9):e04830. doi:10.1016/j.heliyon.2020.e04830.
- Mazza C, Breton R, Housset D, Fontecilla-Camps JC. 1998. Unusual charge stabilization of NADP⁺ in 17 β -hydroxysteroid dehydrogenase. *J Biol Chem*. 273(14):8145–8152. doi:10.1074/jbc.273.14.8145.
- Meirson T, Gil-Henn H, Samson AO. 2020. Invasion and metastasis: the elusive hallmark of cancer. *Oncogene*. 39(9):2024–2026. doi:10.1038/s41388-019-1110-1.
- Meng X, Zhang H, Mezei M, Cui M. 2011. Molecular Docking: a powerful approach for structure based drug discovery. *Curr Comput Aided Drug Des*. 7(2):146–157. doi:10.47583/ijpsrr.2022.v77i02.029.
- Micheli L, Ferrara V, Akande T, Khatib M, Salawu SO, Ciampi C, Lucarini E, Di Cesare Mannelli L, Mulinacci N, Ghelardini C. 2023. Ellagitannins and triterpenoids extracts of *Anogeissus leiocarpus* stem bark extracts: protective effects against osteoarthritis. *Phytother Res*. 37(6):2381–2394. doi:10.1002/ptr.7760.
- Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods*. 65(1-2):55–63. doi:10.1016/0022-1759(83)90303-4.
- Naaz F, Haider MR, Shafi S, Yar MS. 2019. Anti-tubulin agents of natural origin: targeting taxol, vinca, and colchicine binding domains. *Eur J Med Chem*. 171:310–331. doi:10.1016/j.ejmech.2019.03.025.
- Nduji AA, Okwute SK. 1988. Co-occurrence of 3,3',4'-tri-O-methylflavellagtc acid and 3,3',-di-O-methyllellagtc acid in the bark of *Anogeissus schimperi*. *Phytochemistry*. 27(5):1548–1550.
- Newman DJ, Cragg GM. 2020. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J Nat Prod*. 83(3):770–803. doi:10.1021/acs.jnatprod.9b01285.
- Ofukwu RA, Ayoola A, Akwuobu CA. 2008. Medicinal plants used in the treatment of tuberculosis in humans and animals by Idoma tribe of North Central Nigeria. *Niger Vet J*. 29(2): 25–30.
- Oluoyemi WM, Samuel BB, Adewumi AT, Adekunle YA, Soliman MES, Krenn L. 2022. An allosteric inhibitory potential of triterpenes from *Combretum racemosum* on the structural and functional dynamics of *Plasmodium falciparum* lactate dehydrogenase binding landscape. *Chem Biodivers*. 19(2):e202100646. doi:10.1002/cbdv.202100646.
- Orlando G, Ferrante C, Zengin G, Sinan KI, Bene K, Diuzheva A, Jekő J, Cziáky Z, Simone D, Recinella S, et al. 2019. Qualitative chemical characterization and multidirectional biological investigation of leaves and bark extracts of *Anogeissus leiocarpus* (DC.) Guill. & Perr. (Combretaceae). *Antioxidants*. 8(9):343. doi:10.3390/antiox8090343.
- Petterson EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera-A visualization system for exploratory research and analysis. *J Comput Chem*. 25(13):1605–1612. doi:10.1002/jcc.20084.
- Pettit GR, Meng Y, Herald DL, Graham KAN, Pettit RK, Doubek DL. 2003. Isolation and structure of ruprechstyryl from *Ruprechtia tangarana*. *J Nat Prod*. 66(8):1065–1069. doi:10.1021/np0300986.
- Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. 2004. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. *Nature*. 428(6979):198–202. doi:10.1038/nature02393.
- Row LR, Raju RR. 1967. Chemistry of *Terminalia* species – XI Isolation of 3,4,3'-O-trimethylflavellagic acid from *Terminalia paniculata* Roth. *Tetrahedron*. 23(2):879–884. doi:10.1016/0040-4020(67)85036-1.
- Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR. 2009. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. *Clin Cancer Res*. 15(9):3094–3102. doi:10.1158/1078-0432.CCR-08-2445.

- Salau AK, Yakubu MT, Oladiji AT. 2013. Cytotoxic activity of aqueous extracts of *Anogeissus leiocarpus* and *Terminalia avicennioides* root barks against Ehrlich Ascites Carcinoma cells. *Indian J Pharmacol.* 45(4):381–385. doi:10.4103/0253-7613.115023.
- Salih EYA, Kanninen M, Sipi M, Luukkanen O, Hiltunen R, Vuorela H, Julkunen-Tiitto R, Fyhrquist P. 2017. Tannins, flavonoids and stilbenes in extracts of African savanna woodland trees *Terminalia brownii*, *Terminalia laxiflora* and *Anogeissus leiocarpus* showing promising antibacterial potential. *S Afr J Bot.* 108:370–386. doi:10.1016/j.sajb.2016.08.020.
- Samuel BB, Adekunle YA. 2021. Isolation and structure elucidation of anti-malarial principles from *Terminalia mantaly* H. Perrier stem bark. *Int J Bio Chem Sci.* 15(1):282–292. doi:10.4314/ijbcs.v15i1.25.
- Sanogo Y, Soro D, Kanga Y. 2023. Ethnobotanical study of medicinal plants used for the treatment of malaria in the department of Korhogo in the north of Côte d'Ivoire. *World J Adv Res Rev.* 20(1):540–553. doi:10.30574/wjarr.2023.20.1.1842.
- Sarker SD, Nahar L, Miron A, Guo M. 2020. Anticancer natural products. In: Annual Reports in Medicinal Chemistry. Satyajit D. Sarker, Lutfun Nahar (Eds.). 1st ed. Academic Press. Elsevier Inc., vol. 55; p. 45–75. doi:10.1016/bs.armc.2020.02.001.
- Serafin C, Nart V, Malheiros A, de Souza MM, Fischer L, Monache GD, Monache FD, Filho VC. 2007. Bioactive phenolic compounds from aerial parts of *Plinia glomerata*. *Z Naturforsch C J Biosci.* 62(3-4):196–200. doi:10.1515/znc-2007-3-407.
- Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. 1998. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell.* 95(7):927–937. doi:10.1016/S0092-8674(00)81717-1.
- Shuaibu MN, Wuyep PA, Yanagi T, Hirayama K, Tanaka T, Kouno I. 2008. The use of microfluorometric method for activity-guided isolation of antiplasmodial compound from plant extracts. *Parasitol Res.* 102(6):1119–1127. doi:10.1007/s00436-008-0879-6.
- Singh D, Baghel US, Gautam A, Baghel DS, Yadav D, Malik J, Yadav R. 2016. The genus *Anogeissus*: a review on ethnopharmacology, phytochemistry and pharmacology. *J Ethnopharmacol.* 194:30–56. doi:10.1016/j.jep.2016.08.025.
- Stamos J, Sliwkowski MX, Eigenbrot C. 2002. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. *J Biol Chem.* 277(48):46265–46272. doi:10.1074/jbc.M207135200.
- Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 71(3):209–249. doi:10.3322/caac.21660.
- Taiwo O, Xu H, Lee SF. 1999. Antibacterial activities of extracts from Nigerian chewing sticks. *Phytother Res.* 13(8):675–679. doi:10.1002/(SICI)1099-1573(199912)13:8<675::AID-PTR513>3.3.CO;2-O.
- Thomsen R, Christensen MH. 2006. MolDock: a new technique for high-accuracy molecular docking. *J Med Chem.* 49(11):3315–3321. doi:10.1021/jm051197e.
- Trott O, Olson AJ. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem.* 31(2):455–461. doi:10.1002/jcc.21334.
- Tuszyński JA, Brown JA, Crawford E, Carpenter EJ, Nip MLA, Dixon JM, Sataric MV. 2005. Molecular dynamics simulations of tubulin structure and calculations of electrostatic properties of microtubules. *Math Comput Model.* 41(10):1055–1070. doi:10.1016/j.mcm.2005.05.002.
- Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL. 2000. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. *Mol Cell.* 6(4):909–919. doi:10.1016/S1097-2765(05)00089-4.
- Wang J, Miller DD, Li W. 2022. Molecular interactions at the colchicine binding site in tubulin: an X-ray crystallography perspective. *Drug Discov Today.* 27(3):759–776. doi:10.1016/j.drudis.2021.12.001.
- Wild CP, Weiderpass E, Stewart BW. 2020. World cancer report: cancer research for cancer prevention. International Agency for Research on Cancer. Available from: <http://publications.iarc.fr/586>. Licence: CC BY-NC-ND 3.0 IGO.